Back to results
US 9,040,528 B2Granted
Chemical compounds 542
AssigneeAstraZeneca AB
InventorsKevin Barvian, Gregory Steven Basarab, Madhusudhan Reddy Gowravaram, Sheila Irene Hauck, Fei Zhou
Life of this patent
Estimating the term…
Abstract
The present invention relates to compounds of Formula (I): to pharmaceutically acceptable salts thereof, to methods of using them to treat bacterial infections, and to methods for their preparation.
Claims14
A method for treating a bacterial infection in a warm-blooded animal, said method comprising administering to said animal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof,
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is a fused morpholine optionally substituted on carbon with one or two R4;
- W is —O or —S—
- X is N or C—H:
- Y is N or C—R3;
- R1 is selected from halo, —CN, C1-6alkyl, carbocyclyl, heterocyclyl, —OR1a, —N(R1a)2, and —C(O)N(R1a)2, wherein said C1-6alkyl, carbocyclyl, and heterocyclyl are optionally substituted on carbon with one or more R10, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with R10*;
- R1a in each occurrence is independently selected from H, C1-6alkyl, carbocyclyl, and heterocyclyl, wherein said C1-6alkyl, carbocyclyl, and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more R10, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with R10*;
- R1b is C1-6alkyl;
- R3 is chlorine, fluorine or methyl;
- R4 is methyl;
- R10 in each occurrence is independently selected from —CN, C1-6alkyl, carbocyclyl, heterocyclyl, —OR10a, —SR10a, —N(R10a)2, —N(R10a)C(O)R10b, —C(O)R10b, —C(O)2R10a, —C(O)N(R10a)2, and wherein said C1-6alkyl, carbocyclyl and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more Ra, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with Ra*;
- R10* in each occurrence is independently selected from C1-6alkyl, —C(O)R10b and —C(O)2R10a, wherein said C1-6alkyl each occurrence is optionally and independently substituted on carbon with one or more Ra;
- R10a in each occurrence is independently selected from H, C1-6alkyl and heterocyclyl, wherein said C1-6alkyl and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more Ra, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with Ra*;
- Ra in each occurrence is independently selected from halo, —CN, C1-6alkyl and —ORm;
- Ra* in each occurrence is C1-6alkyl;
- and
- Rm in each occurrence is independently selected from H, C1-6alkyl, carbocyclyl, and heterocyclyl.
14 more elements
A method of producing a bacterial DNA gyrase inhibitory effect in a warm blooded animal comprising administering to the warm blooded animal an effective amount of a compound of Formula (I):
- or a pharmaceutically acceptable salt thereof,
- or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is a fused morpholine optionally substituted on carbon with one or two R4;
- W is —O or —S—
- X is N or C—H;
- Y is N or C—R3;
- R1 is selected from halo, —CN, C1-6alkyl, carbocyclyl, heterocyclyl, —OR1a, —N(R1a)2, and —C(O)N(R1a)2, wherein said C1-6alkyl, carbocyclyl, and heterocyclyl are optionally substituted on carbon with one or more R10, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with R10*;
- R1a in each occurrence is independently selected from H, C1-6alkyl, carbocyclyl, and heterocyclyl, wherein said C1-6alkyl, carbocyclyl, and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more R10, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with R10*;
- R1b is C1-6alkyl;
- R3 is chlorine, fluorine or methyl;
- R4 is methyl;
- R10 in each occurrence is independently selected from —CN, C1-6alkyl, carbocyclyl, heterocyclyl, —OR10a, —SR10a, —N(R10a)2, —N(R10a)C(O)R10b, —C(O)R10b, —C(O)2R10a, —C(O)N(R10a)2, and wherein said C1-6alkyl, carbocyclyl and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more Ra, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with Ra*;
- R10* in each occurrence is independently selected from C1-6alkyl, —C(O)R10b and —C(O)2R10a, wherein said C1-6alkyl each occurrence is optionally and independently substituted on carbon with one or more Ra;
- R10a in each occurrence is independently selected from H, C1-6alkyl and heterocyclyl, wherein said C1-6alkyl and heterocyclyl in each occurrence are optionally and independently substituted on carbon with one or more Ra, and wherein any —NH— moiety of said heterocyclyl is optionally substituted with Ra*;
- Ra in each occurrence is independently selected from halo, —CN, C1-6alkyl and —ORm;
- Ra* in each occurrence is C1-6 alkyl;
- and
- Rm in each occurrence is independently selected from H, C1-6 alkyl, carbocyclyl, and heterocyclyl.
15 more elements
Dependencies are inferred from the claim text.